Tango Therapeutics (TNGX) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $15.9 million.
- Tango Therapeutics' Net Income towards Common Stockholders rose 15445.88% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.5 million, marking a year-over-year increase of 1856.67%. This contributed to the annual value of -$130.3 million for FY2024, which is 2806.85% down from last year.
- Per Tango Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $15.9 million for Q3 2025, which was up 15445.88% from -$38.9 million recorded in Q2 2025.
- Tango Therapeutics' 5-year Net Income towards Common Stockholders high stood at $15.9 million for Q3 2025, and its period low was -$39.9 million during Q1 2025.
- Over the past 5 years, Tango Therapeutics' median Net Income towards Common Stockholders value was -$25.6 million (recorded in 2024), while the average stood at -$24.1 million.
- In the last 5 years, Tango Therapeutics' Net Income towards Common Stockholders crashed by 16189173.73% in 2021 and then skyrocketed by 15445.88% in 2025.
- Over the past 5 years, Tango Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$22.1 million in 2021, then tumbled by 31.98% to -$29.1 million in 2022, then decreased by 5.65% to -$30.8 million in 2023, then decreased by 22.37% to -$37.6 million in 2024, then surged by 142.21% to $15.9 million in 2025.
- Its last three reported values are $15.9 million in Q3 2025, -$38.9 million for Q2 2025, and -$39.9 million during Q1 2025.